Odyssey Therapeutics reports Q2 2026 results, plans next OD-001 trials in second half of 2026
The company said Phase 2a monotherapy data on OD-001 will be presented in October, with a combination trial and a Phase 2b trial slated to start later in 2026, backed by $433.1 million in cash.
Odyssey Therapeutics reported financial results for the quarter ended June 30, 2026 on August 4, 2026, along with a pipeline update. Treatment with the company's lead candidate OD-001, a RIPK2 scaffolding inhibitor, in the Phase 2a expansion cohort is now complete, with updated safety and efficacy results from the full induction dataset expected to be presented in an oral presentation at United European Gastroenterology Week in October.1
Odyssey said it continues to expect the RIPK2 program to move into its next stage of clinical development, with a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab expected to begin in the second half of 2026, with more details on both studies to be shared later in the year.1 Topline induction data from both of those studies are expected in the second half of 2027.1
For the second program, Odyssey plans to complete IND-enabling studies and file a clinical trial application for OD-002, an oral SLC15A4 inhibitor, in the second half of 2026, which would allow a Phase 1/2a trial to start in the first half of 2027 in healthy participants, followed by patient cohorts across diseases including cutaneous lupus erythematosus and other autoimmune conditions.1
On finances, Odyssey had cash, cash equivalents and marketable securities of $433.1 million as of June 30, 2026, which the company said are expected to fund operations into the second half of 2028.1 Net loss for the quarter was $52.8 million, compared with $41.2 million for the same period in 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.